PCSA

Processa Pharmaceuticals, Inc. (PCSA) ESG Analysis Analysis (2026)

Invetso Score: 5.4/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.0 (Moderate)

PCSA provides no disclosed environmental metrics in the supplied filings data, leaving its peer-relative environmental positioning difficult to verify versus more transparent healthcare peers.

The absence of reported R&D intensity and capital-efficiency detail limits evidence of environmental process discipline, while peers with fuller disclosure can demonstrate stronger oversight.

No material environmental controversies are provided, so the company avoids a clear disadvantage, but its disclosure depth appears weaker than best-in-class peers.

Given the limited dataset, environmental risk assessment is constrained more by missing information than by demonstrated operational strengths relative to peers.

Social

Score:

The provided data do not include workforce, patient, or community metrics, which weakens peer-relative assessment of social practices against more transparent healthcare issuers.

Zero reported stock-based compensation to revenue offers little evidence of employee-alignment disclosure, whereas peers often provide clearer human-capital transparency.

No social controversies are indicated in the supplied information, but the lack of measurable social indicators prevents a stronger relative score.

Overall social positioning appears neutral to slightly below peers on disclosure quality, rather than on any confirmed social misconduct.

Governance

Score:

Reported debt-to-equity of zero and very low net debt to EBITDA suggest a conservative balance-sheet posture, which is generally favorable versus more leveraged peers.

However, the supplied metrics do not cover board independence, audit quality, or shareholder rights, limiting confidence in a stronger governance assessment.

Zero stock-based compensation to revenue may indicate restrained dilution, but it also provides limited insight into executive incentive design relative to peers.

With no disclosed governance controversies, PCSA appears broadly average, though its governance evidence base is thinner than that of better-disclosed peers.

Overall Score

Score:

PCSA’s ESG profile is broadly average versus peers, with limited disclosed controversies offset by materially weaker transparency across environmental, social, and governance indicators.

Score Driver: Sparse ESG Disclosure Relative To Peers

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Processa Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →